Walsh and Wilkinson
Walsh and Wilkinson

Paul Weiss litigation partners Beth Wilkinson and Alexandra Walsh were part of a team that recently achieved a victory for Pfizer Inc. when a federal court granted the company’s motion for summary judgment. The U.S. District Court for the Southern District of New York ruling in In Re Pfizer Inc. Securities Litigation dismissed the securities class action case in its entirety, according to the firm. The litigation involved decade-old disclosures related to Celebrex and Bextra.

“This was a major victory after a decade-long fight against these allegations,” Walsh told WIPL. “We are extremely gratified that the court recognized the fundamental deficiencies in the plaintiffs’ claims and dismissed the case before trial.”

The ruling by U.S. District Judge Laura Taylor Swain came ahead of a Sept. 9 trial in the case, which investors launched in 2004. It followed an earlier ruling precluding testimony by the plaintiffs’ damages expert.

“We are thrilled about the outcome,” said Wilkinson. “And it was especially satisfying to work again with Pfizer’s top-notch legal team.”

Wilkinson focuses her practice on general litigation and has amassed a broad range of experience, with a particular emphasis in white-collar criminal defense, internal investigations, product liability and complex civil litigation.

Walsh focuses her practice on securities and white collar criminal litigation at the trial and appellate level. She also focuses on internal corporate investigations, including those involving potential issues under the Foreign Corrupt Practices Act.